A case control study defining genetic and nongenetic determinants for treatment-limiting renal tubular injury in HIV infected individuals exposed to tenofovir disoproxil fumarate

Trial Profile

A case control study defining genetic and nongenetic determinants for treatment-limiting renal tubular injury in HIV infected individuals exposed to tenofovir disoproxil fumarate

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 11 Feb 2016 Accural to date is 124% as reported by United Kingdom Clinical Research Network.
    • 11 Feb 2016 Planned End Date changed from 3 Aug 2014 to 30 Nov 2015 as reported by United Kingdom Clinical Research Network.
    • 11 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top